Spruce Biosciences Terminates $65M Tildacerfont Collaboration with Kaken, Solidifying Program Discontinuation

summarizeSummary

Spruce Biosciences has terminated its collaboration and license agreement with Kaken Pharmaceutical, forfeiting up to $65 million in potential future milestone payments and royalties for its tildacerfont program in Japan. This action follows the company's prior disclosure of discontinuing a key Phase 2 clinical trial for tildacerfont.

check_boxKey Events

• Collaboration Termination

  Spruce Biosciences and Kaken Pharmaceutical mutually agreed to terminate their Collaboration and License Agreement for tildacerfont in Japan, effective March 31, 2026.

• Loss of Future Revenue Potential

  The termination results in Spruce Biosciences forfeiting up to approximately $65 million in previously disclosed but unearned milestone payments and royalties from Kaken.

• Program Discontinuation Confirmed

  This action follows a "comprehensive assessment" of the tildacerfont program for CAH and aligns with the company's earlier disclosure in its 10-K from March 9, 2026, of discontinuing a key Phase 2 clinical trial for the asset.

• No Termination Penalties

  Spruce Biosciences incurred no early termination penalties in connection with the Termination Agreement.

auto_awesomeAnalysis

This 8-K filing confirms the termination of a material collaboration agreement for tildacerfont, a program previously identified as having a discontinued Phase 2 trial. For a company facing "going concern" doubts, the loss of up to $65 million in potential future milestone payments and royalties, while unearned, represents a significant blow to its long-term revenue prospects. This move solidifies the company's strategic pivot away from tildacerfont for CAH, as highlighted in recent corporate updates focusing on its TA-ERT program. Investors should view this as a negative development, further emphasizing the company's need to successfully advance its remaining pipeline assets.